3 withdrawn. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
| Phase 1 | 2 | Withdrawn 2 |
Follow poly ICLC: new trials by email Literature Review of poly ICLC trials Research Report on poly ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC Poly ICLC, IVIG - Stage IV NSCLC | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2024-06-04 | 2024-09-19 | |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients Pembrolizumab, CDX-1401, Poly-ICLC - Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2017-01-01 | 2016-12-07 | |
| A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma Bevacizumab, Peptide Vaccine, Poly-ICLC as immune adjuvant - Glioblastoma, Glioma | Phase 2 | Withdrawn | NYU Langone Health | 2016-11-01 | 2020-01-13 |
Carcinoma, Non-Small-Cell Lung (2) · Glioblastoma (1) · Glioma (1) · Melanoma (1) · Mesothelioma (1) · Neoplasms (1) · Small Cell Lung Carcinoma (1)
Case Comprehensive Cancer Center (1) · NYU Langone Health (1) · VA Office of Research and Development (1)
United States (2)
Farrah Kheradmand, MD (1) · Sharon Gardner, MD (1) · Vamsidhar Velcheti, MD (1)